-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Dalzanemdor in Huntington Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Dalzanemdor in Huntington Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Dalzanemdor in Huntington Disease Drug Details: Dalzanemdor (SAGE-718) is under development for...
-
Product Insights
Huntington Disease – Drugs In Development, 2023
Global Markets Direct’s, ‘Huntington Disease - Drugs In Development, 2023’, provides an overview of the Huntington Disease pipeline landscape. The report provides comprehensive information on the therapeutics under development for Huntington Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
NewLikelihood of Approval Analysis for Mutational Disorders
Overview How likely is it that the drugs in Mutational Disorders will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Mutational Disorders Overview Mutational disorders, alternatively termed genetic or genomic disorders, stem...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Valbenazine Tosylate in Trichotillomania
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Valbenazine Tosylate in Trichotillomania report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Valbenazine Tosylate in Trichotillomania Drug Details: Valbenazine tosylate (NBI-98854, Ingrezza) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tominersen in Huntington Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tominersen in Huntington Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Tominersen in Huntington DiseaseDrug Details:Tominersen (RG-6042) is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Valbenazine Tosylate in Schizophrenia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Valbenazine Tosylate in Schizophrenia report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Valbenazine Tosylate in Schizophrenia Drug Details: Valbenazine tosylate (NBI-98854, Ingrezza) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ifezuntirgene Inilparvovec in Huntington Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ifezuntirgene Inilparvovec in Huntington Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ifezuntirgene Inilparvovec in Huntington Disease Drug Details: Ifezuntirgene inilparvovec (AMT-130) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ANX-005 in Huntington Disease
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. ANX-005 in Huntington Disease Drug Details: ANX-005 is under development for the treatment and acute...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MBF-015 in Huntington Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MBF-015 in Huntington Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MBF-015 in Huntington Disease Drug Details: MBF-015 is under development for the...